Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Laura Sun"'
Autor:
Rajbharan Yadav, Siddharth Sukumaran, Tanja S. Zabka, Jinze Li, Amy Oldendorp, Gary Morrow, Arthur Reyes, Melissa Cheu, Jessica Li, Jeffrey J. Wallin, Siao Tsai, Laura Sun, Peiyin Wang, Diego Ellerman, Christoph Spiess, Andy Polson, Eric G. Stefanich, Amrita V. Kamath, Meric A. Ovacik
Publikováno v:
Pharmaceutics, Vol 14, Iss 5, p 970 (2022)
The T cell-dependent bispecific (TDB) antibody, anti-CD79b/CD3, targets CD79b and CD3 cell-surface receptors expressed on B cells and T cells, respectively. Since the anti-CD79b arm of this TDB binds only to human CD79b, a surrogate TDB that binds to
Externí odkaz:
https://doaj.org/article/c576a9c94d774c0bbfd8b9f7d710cb3d
Autor:
Neil Risch, Manuel Seraydarian, Thomas J. Hoffmann, Laura Sun, Marisa W. Medina, Carlos Iribarren, Brian Lu, Ronald M. Krauss, Akinyemi Oni-Orisan
Publikováno v:
Clin Pharmacol Ther
Clinical pharmacology and therapeutics, vol 110, iss 3
Clinical pharmacology and therapeutics, vol 110, iss 3
The association between the c.521T>C variant allele in SLCO1B1 (reference single nucleotide polymorphism (rs)4149056) and simvastatin-induced myotoxicity was discovered over a decade ago; however, whether this relationship represents a class effect i
Autor:
Laura Sun, Kathryn T. Maples, Kevin H. Hall, Yuan Liu, Yichun Cao, Nisha S. Joseph, Craig C Hofmeister, Jonathan L. Kaufman, Madhav Dhodapkar, Ajay K. Nooka, Sagar Lonial, R Donald Harvey
Publikováno v:
Blood. 140:7131-7132
Publikováno v:
Cancer Research. 82:2896-2896
Background: Neuroendocrine Prostate Cancer (NEPC) is an aggressive variant of prostate cancer that can arise de novo or emerge during prostate cancer progression as a mechanism of therapy resistance. The development of effective therapies for patient
Autor:
Laura Sun, Patrick Ng, Abdel Kareem Azab, Wade Aaron, Evan Callihan, Che-Leung Law, Golzar Hemmati
Publikováno v:
Blood. 138:1185-1185
Introduction B-cell maturation antigen (BCMA) is a cell surface receptor highly and selectively expressed on normal plasma cells and transformed plasma cells in multiple myeloma (MM) patients. Upon ligand binding, BCMA initiates signals that promote
Autor:
Henning Schade, Sumit Madan, Xavier Leleu, Jens Hillengass, Liping Laura Sun, William I. Bensinger, Rajneesh Nath, Andrew J. Cowan, Caitlin Costello, Brea Lipe, Al-Ola Abdallah, Eva Medvedova
Publikováno v:
Blood. 138:1654-1654
Background B cell maturation antigen (BCMA) is a clinically validated target for multiple myeloma (MM) based on its restricted expression profile and potential functional role in promoting MM cell survival. HPN217 is a BCMA-targeting T cell engager d
Autor:
Laura Sūna, Dagmar Hoffmann
Publikováno v:
MedienPädagogik: Zeitschrift für Theorie und Praxis der Medienbildung, Vol 2024, Iss Occasional Papers (2024)
Der Beitrag analysiert, wie Künstliche Intelligenz (KI) und die zugehörigen Medienkompetenzen in Online-Kommentarspalten von Nutzer:innen verhandelt werden. Im Zentrum der empirischen Untersuchung stehen Online-Kommentare, die auf Nachrichtenportal
Externí odkaz:
https://doaj.org/article/9b737545767b4e0a9e2ddce69487156d
Autor:
Lisa Knapp, Eva Medvedova, Henning Schade, Rajneesh Nath, Sumit Madan, Liping Laura Sun, Lemon Bryan D
Publikováno v:
Blood. 136:10-10
Background B cell maturation antigen (BCMA) has emerged as a promising target for multiple myeloma (MM) therapies based on its restricted expression profile and functional role in promoting MM cell survival. Some of these BCMA targeting molecules, in
Autor:
Golzar Hemmati, Holger Wesche, Richard J. Austin, Thomas Evans, Mary Ellen Molloy, Kathryn Kwant, Llewelyn Lao, Vaishnavi Ganti, Stephen Yu, Jessica O’Rear, Che-Leung Law, Lemon Bryan D, Michael Cremin, Wade Aaron, Evan Callihan, Laura Sun, Manasi Barath, Timothy Yu, Maria Gamez
Publikováno v:
Molecular Cancer Therapeutics. 18:C033-C033
HPN328: An Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer Delta-like protein 3 (DLL3) is a Notch inhibitory ligand is expressed in more than 70% of small cell lung cancers (SCLCs), while there is little to no surface expression in n
Autor:
Natalie Dimier, Ian W. Flinn, Antonia Kwan, Lihua E. Budde, Hong Wang, Sung-Soo Yoon, Cindy Zhang, Chi-Chung Li, Shen Yin, Joanne I. Adamkewicz, Genevive Hernandez, Brendan Bender, Carol O'Hear, Sue-Zen Lim, Zao Li, Michael C. Wei, Laura Sun, Chunze Li, Laurie H. Sehn
Publikováno v:
Blood. 134:1285-1285
Introduction: Mosunetuzumab (M; RG7828) is a full-length, fully humanized immunoglobulin G1 (IgG1) bispecific antibody targeting both CD3 (on the surface of T cells) and CD20 (on the surface of B cells). Clinical data from GO29781 (NCT02500407), a Ph